Overview

Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.

Status:
Active, not recruiting
Trial end date:
2022-02-11
Target enrollment:
Participant gender:
Summary
This study is to find out if INC280 is safe and has beneficial effects in patients with advanced hepatocellular carcinoma known to have dysregulation of c-MET pathway.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals